Abstract
Activating mutations of the stem cell factor receptor tyrosine kinase (c-Kit) or platelet-derived growth factor receptor α (PDGFRA) can be found in at least 85% of cases of gastrointestinal stromal tumors. The therapeutic options include surgery, local treatment and systemic treatment with tyrosine kinase inhibitors, such as imatinib or sunitinib. Kinase inhibitor-based treatment is used in neoadjuvant, adjuvant and metastatic settings. Knowledge of the individual mutational status allows prediction of response to first-line medical treatment and provides information which can guide selection of the appropriate second-line therapy.
| Translated title of the contribution | Mutational status based therapy algorithm for gastrointestinal stroma tumors. Does c-Kit/PDGFRA mutational analysis affect treatment decisions? |
|---|---|
| Original language | German |
| Journal | Gastroenterologe |
| Volume | 7 |
| Issue number | 1 |
| Pages (from-to) | 30-36 |
| Number of pages | 7 |
| ISSN | 1861-9681 |
| DOIs | |
| Publication status | Published - 01.2012 |
Funding
Das Rezidivrisiko bei Lokalisation im Magen ist deutlich geringer als bei Lokalisation im Dünndarm [25]. Allgemein gebräuchlich und am besten validiert zur Abschätzung des Rezidivrisikos sind die AFIP(Armed Forces Institute of Pathology)Miettinen Kriterien [61] sowie die modifizierten NIH(National Institutes of Health)Joensuu Kriterien, in die zusätzlich die Tumorruptur eingeht [47].
